Buprenorphine for Chronic Pain

Different buprenorphine formulations for chronic pain have several potential advantages over other opioids with respect to cost and logistics.

Buprenorphine for Chronic Pain — Evidence Rating: Moderate Quality

Buprenorphine is an FDA-approved medication for the treatment of chronic pain that can be prescribed from a clinician’s office and filled at a pharmacy. Research data supporting the effectiveness of buprenorphine come from multiple randomized clinical trials and observational studies demonstrating that buprenorphine can reduce pain comparable to full agonist opioids, and offers a safer alternative to full agonist opioids with notably reduced likelihood of severe adverse events, including fatal overdose. While short-term analgesic efficacy is well documented, evidence for benefit beyond 16 weeks of treatment is lacking, as most trials do not extend past 16 weeks. Buprenorphine remains underutilized in the chronic pain management world largely due to a lack of comfort around prescribing and management practices for both care recipients and providers. Several considerations to bolster appropriate buprenorphine utilization for chronic pain are discussed in this evidence-based practice guide.

Evidence-based Scale

The skin patch is available as a generic product and is often covered by insurance plans. Individuals can apply skin patches on their own, typically every seven days, offering easy self-administration. The dissolvable film is not yet available as a generic product, often resulting in higher costs to individuals. Insurance often covers Belbuca, the dissolvable, though it may require prior authorization. The film can be self-administered to the inner cheek every 12 hours, a stricter dosing schedule relative to the patch.

Buprenorphine is often more expensive than generic full agonist opioids (e.g., morphine, oxycodone) due to the lack of widespread availability of the generic chronic pain formulations. Insurance coverage is typically favorable for both buprenorphine and full agonist opioids, though buprenorphine may require prior authorization in some plans. Copays for both buprenorphine and full agonist opioids vary based on plan specifics.

Buprenorphine offers potential logistical advantages over other opioids due to its less frequent dosing (weekly patch vs. daily pills) and lower misuse potential, reducing the need for frequent monitoring. Full agonist opioids require more frequent dosing and monitoring for misuse and side effects.

Buprenorphine may be more cost-effective than full agonist opioids in the long term, due to lower risk of dose escalation, fewer office visits for monitoring, and reduced likelihood of overdose, hospitalization, and complications resulting in fewer potential downstream healthcare costs.